Legend Biotech Corporation American Depositary Shares (9LB)
XMUN 
Summary
9LB Chart
Legend Biotech Jumps 42% On New Data -- Here's What Comes Next
Legend Biotech (LEGN) remains a buy as Carvykti's earlier-line use drives superior efficacy, safety, and manufacturing success, signaling a structural shift in multiple myeloma therapy. Recent CARTITUDE-4 data show earlier Carvykti use extends progression-free and overall survival, with Parkinsonism rates falling below 1%, reinforcing its clinical and commercial momentum. LB2102's early Phase 1 results in solid tumors, with up to 28.6% ORR and manageable toxicity, offer promising optionality beyond hematologic cancers, though confirmation in larger trials is needed.
Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript
Legend Biotech Corporation (LEGN) Shareholder/Analyst Call Transcript
Legend Biotech Conference Spotlights CARVYKTI's Curative Potential, Earlier Use
Legend Biotech NASDAQ: LEGN used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma developed, manufactured and co-promoted with Johnson & Johnson.
Legend Biotech Corporation American Depositary Shares (9LB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Legend Biotech Corporation American Depositary Shares ever had a stock split?
Legend Biotech Corporation American Depositary Shares Profile
| Biotechnology Industry | Healthcare Sector | Ying Huang CEO | XMUN Exchange | US52490G1022 ISIN |
| US Country | 2,600 Employees | - Last Dividend | - Last Split | 5 Jun 2020 IPO Date |
Overview
Legend Biotech Corporation, established in 2014 and based in Somerset, New Jersey, operates as a clinical-stage biopharmaceutical company deeply ingrained in the field of cell therapy. With a vivid international footprint, including operations in the United States, China, and other countries worldwide, Legend Biotech is at the forefront of innovating treatment options for cancer and other severe medical conditions. A subsidiary under the umbrella of Genscript Biotech Corporation, the company prides itself on a profound commitment to leveraging cutting-edge science for the development, manufacturing, and commercialization of novel cellular therapies.
Products and Services
LCAR-B38M CAR-T Therapy: This leading product candidate epitomizes Legend Biotech's pioneering work in the domain of chimeric antigen receptor (CAR) T-cell therapies. Specifically designed for the treatment of multiple myeloma (MM), LCAR-B38M showcases the company’s prowess in targeting intractable cancers with precision and innovation. This CAR-T therapy is a testimony to Legend’s commitment to advancing cancer treatment modalities.
Autologous CAR-T Product Candidates: Complementing its flagship product, Legend Biotech boasts a broad portfolio of autologous CAR-T cell product candidates in earlier stages of development. These groundbreaking therapies are directed against a variety of cancers, underscoring the company's versatile approach to oncological research. The range of targeted cancers includes:
- Non-Hodgkins Lymphoma
- Acute lymphoblastic leukemia
- Gastric cancer
- Esophageal cancer
- Pancreatic cancer
- Colorectal cancer
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
This spectrum of targeted therapies illustrates Legend’s dedication to combating a diverse array of malignancies through innovative cellular therapies.
Collaborations and Licensing: A pivotal aspect of Legend Biotech's strategy for enhancing the reach and impact of its therapies are its collaborations with leading biotech entities. A notable partnership exists with Janssen Biotech, Inc., focusing on the development and commercialization of ciltacabtagene autoleucel. Through such alliances, Legend Biotech not only amplifies its research and development capabilities but also ensures that its innovations can be translated into accessible treatments for patients worldwide.
